Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 11 - 20 of about 75   

Articles published

ARNA 4.45 +0.19 (4.46%)
price chart
Sizzling Stock Alert: Novavax, Inc. (NVAX), Arena Pharmaceuticals, Inc.(ARNA ...
Manhattan, NY- October 24, 2014 - (Techsonian) - Novavax, Inc. (NASDAQ:NVAX)revealed that Gregory Glenn, M.D., Senior Vice President, Research and Development at Novavax will present new immunogenicity data from Novavax' RSV F-Protein ...
Related articles »  
Arena Pharmaceuticals Inc. (ARNA) Hits New 52-week Low During October 10 ...
Arena Pharmaceuticals Inc. (ARNA) established a new 52-week low yesterday, and could be a company to watch at the open. After opening at $3.69, Arena Pharmaceuticals Inc. dropped to $3.59 for a new 52-week low. By the closing bell, the company's ...
Related articles »  
Hot Biotech Round Up: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA ...
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) declared that facts from the stage 3 scientific test program for BELVIQ (lorcaserin HCl) CIV will be launched at the American College of Clinical Pharmacy (ACCP) yearly conference held on last ...
News Review: Arena Pharmaceuticals, Inc. (ARNA), Brandywine Realty Trust ...  Techsonian (press release)
Related articles »  
Eisai and Arena Pharmaceuticals Announce Presentation of Lorcaserin HCl ...
WOODCLIFF LAKE, N.J. and SAN DIEGO, Oct. 13, 2014 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for BELVIQ� (lorcaserin HCl) CIV will be presented at the ...
Related articles »  
Stocks to Watch � Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Proto Labs Inc ...
Arena Pharmaceuticals, Inc. (ARNA) a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors.
Stocks Buzz - Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Magnum Hunter ...
Houston, TX - October 28, 2014 - (Techsonian)_Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) released that it will host a conference call and webcast at 8:30 a.m.
Related articles »  
Arena Pharmaceuticals Inc. (ARNA) Hits New 52-week Low During October 13 ...
Arena Pharmaceuticals Inc. (ARNA) established a new 52-week low yesterday, and could be a company to watch at the open. After opening at $3.65, Arena Pharmaceuticals Inc. dropped to $3.26 for a new 52-week low. By the closing bell, the company's ...
Related articles »  
Belviq Sales Dip: What To Watch For Ahead
Sales of the Arena Pharmaceuticals (NASDAQ:ARNA) anti-obesity pill Belviq seem to be seeing some impacts of seasonality with ups and downs as the Fall weeks progress.
Eisai and Arena Pharmaceuticals Announce Publication of Pooled Phase 3 ...
WOODCLIFF LAKE, N.J. and SAN DIEGO, Oct. 10, 2014 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that a pooled analysis of the BLOOM and BLOSSOM pivotal, Phase 3 clinical trials of BELVIQ� ...
Belviq Sales Rise Almost 5% Week Over Week  Seeking Alpha (registration)
Related articles »  
Notable Movers-Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Odyssey Marine ...
Manhattan, NY- October 28, 2014 - (Techsonian) - Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors.